Articles related to CLINICAL TRIALS

In the latest findings on gantenerumab, while the anticipated cognitive benefits in Alzheimer’s patients were not realized, the drug demonstrated significant impacts on biomarkers, including amyloid plaque reduction and alterations in CSF phosphorylated tau and Aβ42 levels.

A 2019 trial report from NEJM offered a comparative analysis of levetiracetam, fosphenytoin, and valproate in managing benzodiazepine-resistant convulsive status epilepticus, providing essential insights into their efficacy and safety, aiding clinicians in informed decision-making.

Explore new horizons in advanced hepatocellular carcinoma treatment with emerging data on lenvatinib and cisplatin’s potential efficacy as a second-line therapy and the promising triple combination therapy showing significant response rates.

Explore the latest insights from ASCO GU 2024 on first-line treatments for advanced renal cell carcinoma, including the effectiveness of combination therapies and the pressing need to address racial disparities in patient outcomes.

Mirvetuximab soravtansine represents a pivotal shift in treating platinum-resistant ovarian cancer, demonstrating not only improved survival outcomes but also a higher response rate compared to standard chemotherapy.

In a recent phase 3 trial, the addition of brentuximab vedotin to standard chemotherapy not only achieved a notable improvement in 3-year event-free survival rates for pediatric Hodgkin’s lymphoma patients but also maintained a comparable safety profile, underscoring the therapeutic potential of targeted treatments in this population.